# Natera

Type: Company (NTRA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/natera
Canonical HTML page: https://getbiobrief.com/entity/natera

## Recent coverage (1 stories)

### Natera and Lantheus Earnings: Precision Diagnostics and Radiopharma in Focus
2026-02-25 05:15:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Full story: https://getbiobrief.com/story/natera-lantheus-earnings-preview-biotech-diagnostics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.